Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

43.78USD
17 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$43.78
Open
$44.24
Day's High
$44.26
Day's Low
$43.40
Volume
89,068
Avg. Vol
201,978
52-wk High
$60.98
52-wk Low
$36.19

Goldstein, Dov 

Dr. Dov A. Goldstein is an independent Director of the Company. He is currently the Chief Financial Officer of Schrödinger Therapeutics. From 2014 to 2017 he was a Managing Partner at Aisling Capital, a private investment firm. He previously served as a Partner of Aisling Capital from 2008 to 2014, and from 2006 to 2008, he was a Principal at Aisling Capital. From June 2014 to January 2015, he served as Chief Financial Officer of Loxo Oncology, Inc. (NASDAQ: LOXO). From 2000 to 2005, Dr. Goldstein was Chief Financial Officer of Vicuron Pharmaceuticals, Inc. before its acquisition by Pfizer Inc. From 1998 to 2000, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures, a privately held investment fund. Dr. Goldstein is a director of ADMA Biologics, Inc. (NASDAQ: ADMA). He previously served as a member of the board of directors of Cempra Pharmaceuticals, Inc. (merged with Melinta Therapeutics), Durata Therapeutics (NASDAQ: DRTX) from December 2009 until May 2013, and of Loxo Oncology (NASDAQ: LOXO) from July 2013 to October 2014. He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 343,846

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --